---
title: "Antihypertensive Drug Class and Risk of Incident Alzheimer’s Disease and Related Dementias: Replic"
id: "medrxiv-17-antihypertensive-medication-class-and-incident-alzheimers-disease-and-related"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-17-antihypertensive-medication-class-and-incident-alzheimers-disease-and-related"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.11.26362859v1?rss=1"
published_at: "2026-09-17T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Antihypertensive Drug Class and Risk of Incident Alzheimer’s Disease and Related Dementias: Replic
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-17-antihypertensive-medication-class-and-incident-alzheimers-disease-and-related
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.11.26362859v1?rss=1)
- **Published At:** 2026-09-17T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This retrospective new-user, active-comparator cohort study evaluated whether predominant use of antihypertensive classes that **stimulate** versus **inhibit** angiotensin II type 2 and type 4 receptor signaling is associated with incident Alzheimer’s disease and related dementias (ADRD). - The study was conducted in parallel across two independent data sources: the Vanderbilt University Medical Center Synthetic Derivative (VUMC SD; deidentified EHR through February 2025) and the Merative MarketScan Medicare Database (2015–2023). - Inclusion criteria: adults aged ≥65 years with hypertension, at least a 365-day blanking period, and ≥365 cumulative days of antihypertensive exposure; predominant use defined as ≥80% of cumulative exposure days. - Exposure groups: receptor-stimulating medications (angiotensin II receptor blockers, dihydropyridine calcium channel blockers, thiazide diuretics), receptor-inhibiting medications (angiotensin-converting enzyme inhibitors, β-blockers, nondihydropyridine calcium channel blockers), and nonusers (no predominant use of either class). - Primary outcome: time to first incident ADRD diagnosis identified using ICD-9 and ICD-10 codes consistent with the CMS Chronic Conditions Data Warehouse definition; analyzed with Cox proportional hazards models with time-dependent covariates and propensity score matching. - Cohort sizes: Medicare n=1,596,034 (mean age 75.0 years, 55% female); VUMC SD n=80,267 (mean age 72.3 years, 57% female). - Over roughly 7 years’ follow-up, crude ADRD incidence was lower in predominant users of stimulating versus inhibiting medications (Medicare: 6.7% vs 8.2%; VUMC SD: 4.9% vs 5.7%). - Adjusted results: predominant use of stimulating agents was associated with lower ADRD risk compared with inhibiting agents in both datasets (Medicare HR 0.92, 95% CI 0.90–0.93; VUMC SD HR 0.92, 95% CI 0.85–0.99), both statistically significant. - Established cardiovascular and neuropsychiatric risk factors (atrial fibrillation, heart failure, chronic kidney disease, depression) demonstrated expected associations with ADRD, supporting internal validity across datasets. - Authors conclude that predominant use of antihypertensives that stimulate angiotensin II type 2 and type 4 signaling was associated with a modestly lower incident ADRD risk and recommend evaluation in randomized comparative-effectiveness trials. Details on some analytic decisions and secondary analyses were not reported in the source abstract.
## Clinical Analysis & Structured Key Points
Antihypertensive Medication Class and Incident Alzheimers Disease and Related Dementias: External Replication Across Two Independent Healthcare Data Sources-the Vanderbilt EHR Synthetic Derivative and US Medicare Claims | medRxiv Skip to main content Antihypertensive Medication Class and Incident Alzheimers Disease and Related Dementias: External Replication Across Two Independent Healthcare Data Sources-the Vanderbilt EHR Synthetic Derivative and US Medicare Claims Anshul Tiwari , Rui Chen , Yuting Tan , Yan Yan , Zhexing Wen , Wei-Qi Wei , View ORCID Profile Xue Zhong , View ORCID Profile Bingshan Li doi: https://doi.org/10.64898/2026.09.11.26362859 Anshul Tiwari 1 Vanderbilt University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site For correspondence: anshul.tiwari{at}vanderbilt.edu Rui Chen 1 Vanderbilt University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Yuting Tan 1 Vanderbilt University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Yan Yan 1 Vanderbilt University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Zhexing Wen 2 Emory University; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Wei-Qi Wei 3 Vanderbilt University Medical Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Xue Zhong 3 Vanderbilt University Medical Center; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Xue Zhong Bingshan Li 4 Vanderbilt University - Nashville, TN Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Bingshan Li Abstract Info/History Metrics Supplementary material Data/Code Preview PDF Abstract Importance. Hypertension is among the most important modifiable risk factors for Alzheimers disease and related dementias (ADRD), but whether different antihypertensive drug classes confer different cognitive risk, particularly through differential modulation of angiotensin II receptor signaling, remains uncertain. Prior pharmacoepidemiologic evidence is based largely on a single Medicare cohort, and external validation across distinct healthcare data environments is needed. Objective. To externally replicate and extend prior findings across two structurally independent healthcare data sources, evaluating whether predominant use of antihypertensive medications that stimulate versus inhibit angiotensin II type 2 and type 4 receptor signaling is associated with risk of incident ADRD. Design, Setting, and Participants. Retrospective new user, active comparator cohort study with propensity score matching, conducted in parallel across two independent data sources: the Vanderbilt University Medical Center Synthetic Derivative (VUMC SD; deidentified academic medical center electronic health record through February 2025) and the Merative MarketScan Medicare Database (2015 to 2023). Adults aged 65 years or older with hypertension and at least 365 cumulative days of antihypertensive exposure were included after a 365-day blanking period. Exposures. Predominant use (≥80% of cumulative exposure days) of receptor-stimulating antihypertensive medications (angiotensin II receptor blockers, dihydropyridine calcium channel blockers, thiazide diuretics) vs receptor-inhibiting antihypertensive medications (angiotensin-converting enzyme inhibitors, βblockers, nondihydropyridine calcium channel blockers); a third group of nonusers comprised participants without predominant use of either class. Main Outcomes and Measures. Time to first incident ADRD diagnosis was identified using ICD9 and ICD10 codes consistent with the CMS Chronic Conditions Data Warehouse definition. Adjusted hazard ratios (HRs) and 95% CIs were estimated using Cox proportional hazards models with time-dependent covariates. Results. The Medicare cohort included 1,596,034 beneficiaries (mean [SD] age, 75.0 [8.0] years; 55% female), and the VUMC SD cohort included 80,267 patients (mean [SD] age, 72.3 [5.8] years; 57% female). Over approximately 7 years of follow-up, ADRD incidence was lower among predominant users of stimulating vs. inhibiting medications in both cohorts (Medicare: 6.7% vs. 8.2%; VUMC SD: 4.9% vs. 5.7%). After adjustment, predominant use of stimulating medications was associated with lower ADRD risk versus inhibiting medications in both cohorts (Medicare: HR, 0.92; 95% CI, 0.90,0.93; P < .001; VUMC SD: HR, 0.92; 95% CI, 0.85,0.99; P = .03). Established cardiovascular and neuropsychiatric risk factors (atrial fibrillation, heart failure, chronic kidney disease, depression) showed expected associations with ADRD risk in both cohorts, supporting internal validity. Conclusions and Relevance. Across two structurally independent data sources, the predominant use of antihypertensive medications that stimulate angiotensin II type 2 and type 4 receptor signaling was associated with a modestly lower risk of incident ADRD compared with predominantly inhibiting agents. By replicating in two distinct data environments, these findings extend prior single-source pharmacoepidemiologic evidence and support evaluation of receptor targeted antihypertensive strategies for cognitive outcomes in randomized comparative-effectiveness trials. Competing Interest Statement The authors have declared no competing interest. Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Retrospective new-user, active-comparator cohort study with propensity-score matching, conducted in parallel across two independent data sources: the Vanderbilt University Medical Center Synthetic Derivative (VUMC SD; deidentified academic medical center electronic health record through February 2025) and the Merative MarketScan Medicare Database (2015 to 2023). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability Certain data used in this study were supplied by Merative as part of one or more MarketScan Research Databases. Any analysis, interpretation, or conclusion based on these data is solely that of the authors and not Merative. Funder Information Declared NIH Common Fund, https://ror.org/001d55x84 , R01AG069900 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Back to top Previous Next Posted September 17, 2026. Download PDF Supplementary Material Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Antihypertensive Medication Class and Incident Alzheimers Disease and Related Dementias: External Replication Across Two Independent Healthcare Data Sources-the Vanderbilt EHR Synthetic Derivative and US Medicare Claims Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Antihypertensive Medication Class and Incident Alzheimers Disease and Related Dementias: External Replication Across Two Independent Healthcare Data Sources-the Vanderbilt EHR Synthetic Derivative and US Medicare Claims Anshul Tiwari , Rui Chen , Yuting Tan , Yan Yan , Zhexing Wen , Wei-Qi Wei , Xue Zhong , Bingshan Li medRxiv 2026.09.11.26362859; doi: https://doi.org/10.64898/2026.09.11.26362859 Share This Article: Copy Citation Tools Antihypertensive Medication Class and Incident Alzheimers Disease and Related Dementias: External Replication Across Two Independent Healthcare Data Sources-the Vanderbilt EHR Synthetic Derivative and US Medicare Claims Anshul Tiwari , Rui Chen , Yuting Tan , Yan Yan , Zhexing Wen , Wei-Qi Wei , Xue Zhong , Bingshan Li medRxiv 2026.09.11.26362859; doi: https://doi.org/10.64898/2026.09.11.26362859 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Areas All Articles Addiction Medicine (617) Allergy and Immunology (902) Anesthesia (334) Cardiovascular Medicine (4819) Dentistry and Oral Medicine (479) Dermatology (415) Emergency Medicine (650) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1629) Epidemiology (15955) Forensic Medicine (33) Gastroenterology (1203) Genetic and Genomic Medicine (7052) Geriatric Medicine (733) Health Economics (1065) Health Informatics (5052) Health Policy (1435) Health Systems and Quality Improvement (1768) Hematology (586) HIV/AIDS (1346) Infectious Diseases (except HIV/AIDS) (16298) Intensive Care and Critical Care Medicine (1173) Medical Education (669) Medical Ethics (155) Nephrology (725) Neurology (7282) Nursing (368) Nutrition (1082) Obstetrics and Gynecology (1241) Occupational and Environmental Health (1005) Oncology (3611) Ophthalmology (1054) Orthopedics (398) Otolaryngology (457) Pain Medicine (470) Palliative Medicine (139) Pathology (709) Pediatrics (1801) Pharmacology and Therapeutics (737) Primary Care Research (767) Psychiatry and Clinical Psychology (5906) Public and Global Health (9762) Radiology and Imaging (2427) Rehabilitation Medicine and Physical Therapy (1454) Respiratory Medicine (1249) Rheumatology (642) Sexual and Reproductive Health (772) Sports Medicine (578) Surgery (780) Toxicology (107) Transplantation (305) Urology (291)
## Related Clinical Research

- [More REM (dream) sleep linked to lower risk of 83 diseases—UK Biobank study](https://medichelpline.com/clinical-feed/medical-news-today-0-more-dream-sleep-linked-to-lower-risk-of-83-diseases-including-diabetes.md)
- [Pre-diagnostic 1-year prevalence of polypharmacy and PIMcog in Norwegian outpatients with MCI or d](https://medichelpline.com/clinical-feed/plos-one-14-one-year-pre-diagnostic-prevalence-and-associated-factors-of-polypharmacy-and.md)
- [Impact of Nighttime Light Exposure on Heart Health and Disease Risk](https://medichelpline.com/clinical-feed/medical-news-today-0-nighttime-light-exposure-may-alter-the-heart-and-increase-disease-risk.md)
- [Infection Does Not Impair Decongestion or Short-Term Kidney Outcomes in Cardiorenal Syndrome Type 1](https://medichelpline.com/clinical-feed/plos-one-11-impact-of-infection-on-decongestion-and-kidney-outcomes-in-patients-with.md)
- [Alzheimer’s Biomarkers in Dental Practice: Risks, Limitations, and Practical Alternatives](https://medichelpline.com/clinical-feed/dentistry-iq-14-alzheimer-s-biomarkers-in-dental-practice-is-innovation-outpacing-readiness.md)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.